Abstract
ARO-ANG3, an investigational RNAI therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolaemia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have